tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Scorpion Stings D065008 1 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Retrognathia D063173 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Candidiasis, Invasive D058365 2 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Netherton Syndrome D056770 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fung JJ Tacrolimus and transplantation: a decade in review. 2004 Transplantation pmid:15201685
Busuttil RW and Lake JR Role of tacrolimus in the evolution of liver transplantation. 2004 Transplantation pmid:15201686
Vincenti F A decade of progress in kidney transplantation. 2004 Transplantation pmid:15201687
Burke GW et al. Advances in pancreas transplantation. 2004 Transplantation pmid:15201688
Pascual J et al. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant. 2006 Transplantation pmid:16861942
Bunnapradist S et al. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. 2003 Transplantation pmid:12865780
Asberg A et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. 2006 Transplantation pmid:16861943
Pfitzmann R et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. 2003 Transplantation pmid:12865798
Sawabe T et al. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. 1997 Transplantation pmid:9233725
Gruessner RW et al. A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. 1995 Transplantation pmid:7530871
Jindal RM et al. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. 1994 Transplantation pmid:7514317
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Drachenberg CB et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. 1999 Transplantation pmid:10459544
Heffron TG et al. Pediatric liver transplantation with daclizumab induction. 2003 Transplantation pmid:12829908
Gonwa T et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. 2003 Transplantation pmid:12829910
Briggs D et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. 2003 Transplantation pmid:12829912
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Shihab FS et al. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. 1997 Transplantation pmid:9422427
Vu MD et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. 1997 Transplantation pmid:9422432
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Valdivia LA et al. Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. 1993 Transplantation pmid:7681230
Shapiro R et al. A prospective randomized trial of FK506-based immunosuppression after renal transplantation. 1995 Transplantation pmid:7533343
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Cox KL et al. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. 1995 Transplantation pmid:7533344
Sakr M et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. 1992 Transplantation pmid:1374948
McDiarmid SV et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. 1995 Transplantation pmid:7533345
Selzner N et al. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience. 2001 Transplantation pmid:11579301
Savoldo B et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. 2001 Transplantation pmid:11579304
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Jain A et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. 2001 Transplantation pmid:11579306
Sanchez-Campos S et al. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. 1998 Transplantation pmid:9679826
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Tsuchiya T et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. 2013 Transplantation pmid:23792649
Barth RN et al. Prolonged survival of composite facial allografts in non-human primates associated with posttransplant lymphoproliferative disorder. 2009 Transplantation pmid:19996923
Newell KA et al. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. 1997 Transplantation pmid:9381541
Iyengar AR et al. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. 1997 Transplantation pmid:9158008
van Hooff JP Pneumocystis carinii pneumonia after renal transplantation. 1997 Transplantation pmid:9158038
Størset E et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 Transplantation pmid:25886918
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Roberts JP et al. Reversal of chronic rejection after treatment failure with FK506 and RS61443. 1993 Transplantation pmid:7692634
Hariharan S et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. 1996 Transplantation pmid:8610411
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Burroughs TE et al. Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients. 2009 Transplantation pmid:19667939
Mittal SK et al. Increased interleukin-10 production without expansion of CD4+CD25+ T-regulatory cells in early stable renal transplant patients on calcineurin inhibitors. 2009 Transplantation pmid:19667950
Coto E and Tavira B Pharmacogenetics of calcineurin inhibitors in renal transplantation. 2009 Transplantation pmid:19667964
Kihm LP et al. Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. 2012 Transplantation pmid:22470107
Hoogtanders K et al. Dried blood spot measurement of tacrolimus is promising for patient monitoring. 2007 Transplantation pmid:17264824
Pérgola PE et al. Kidney transplantation during the first trimester of pregnancy: immunosuppression with mycophenolate mofetil, tacrolimus, and prednisone. 2001 Transplantation pmid:11349738
Neumann UP et al. Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. 2001 Transplantation pmid:11374419
Xie Y et al. Delayed Donor Bone Marrow Infusion Induces Liver Transplant Tolerance. 2017 Transplantation pmid:28187014
Rajesh KG et al. Mitochondrial permeability transition-pore inhibition enhances functional recovery after long-time hypothermic heart preservation. 2003 Transplantation pmid:14627909
Sato T et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. 2003 Transplantation pmid:14627910
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Vignali D et al. IL-7 Mediated Homeostatic Expansion of Human CD4+CD25+FOXP3+ Regulatory T Cells After Depletion With Anti-CD25 Monoclonal Antibody. 2016 Transplantation pmid:27306531
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Homma M et al. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. 2002 Transplantation pmid:11821750
Chakrabarti P et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. 2000 Transplantation pmid:11003353
Arroyo Hornero R et al. CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression. 2017 Transplantation pmid:28118317
Inoue T et al. Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. 2000 Transplantation pmid:11003356
Richards KR et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. 2014 Transplantation pmid:24784360
Chung BH et al. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. 2017 Transplantation pmid:28107277
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Klupp J et al. Indications of mycophenolate mofetil in liver transplantation. 2005 Transplantation pmid:16286893
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
de Fijter JW Tacrolimus dosing in mycophenolate-treated patients--can we get away with less? 2011 Transplantation pmid:21654351
Nankivell BJ et al. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. 2016 Transplantation pmid:27306529
Ko S et al. The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. 1995 Transplantation pmid:7539553
Fealy MJ et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. 1995 Transplantation pmid:7539555
Blakolmer K et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. 2000 Transplantation pmid:10868635
Neuhaus P et al. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial. 2000 Transplantation pmid:10868638
Marin-Casino M et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. 2014 Transplantation pmid:25243519
Miller J et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 2000 Transplantation pmid:10755543
De Ruvo N et al. Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation. 2005 Transplantation pmid:16003226
Mohamed MA et al. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus. 2000 Transplantation pmid:10755567
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
Paterson DL et al. Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. 1998 Transplantation pmid:9753337
Guthery SL et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. 2003 Transplantation pmid:12698085
Guasch A et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. 2010 Transplantation pmid:20811320
Pascual J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. 2004 Transplantation pmid:15599321
Ciancio G et al. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year. 2004 Transplantation pmid:14742989
Wennberg L et al. Preapheresis immunosuppressive induction: necessary or harmful? 2007 Transplantation pmid:18162987
Ciancio G et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. 2004 Transplantation pmid:14742990
Azzola A et al. Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation. 2004 Transplantation pmid:14742993
Ferdman RM et al. Rapid intravenous desensitization to antithymocyte globulin in a patient with aplastic anemia. 2004 Transplantation pmid:14743005
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Hoerning A et al. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity. 2015 Transplantation pmid:25099702
Günther M et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. 2001 Transplantation pmid:11233913
Ekberg H et al. Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation. 2011 Transplantation pmid:21562449
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241